For instance, in various cancer types, including pancreatic cancer and lung cancer where KRAS mutations are key oncogenic drivers (Buscail et al., 2020), several miRNAs (miR-143, miR-145, miR-216, miR-217, and let-7) binding to the 3′ untranslated region (3′UTR) of KRAS mRNA are downregulated, thereby contributing to the hyperactivity of KRAS mutants (Volinia et al., 2006; Szafranska et al., 2007). This evidence concerns the gene KRAS and cancer.